Navigation Links
Eight-Year Melanoma Remission is Among Early Cancer Treatment Results
Date:7/13/2008

NASHVILLE, Tenn., July 14 /PRNewswire/ -- A newly available treatment already has benefited several individuals with aggressive malignancies. Offered through NeoPlas Innovation, this regimen has arrested or eradicated tumors in more than 80% of initial patients. Director of Research Dr. Stephen Cantrell emphasized that human testing is in its early stages, but added, "These results have surprised us. This is far beyond what currently available standard treatments achieve."

Melanoma, a deadly form of malignant skin cancer, is among the diseases targeted to date. The first person treated with the investigative protocol had stage 4 melanoma and a life expectancy of eight weeks. He experienced a complete response and remains disease-free eight years later. While not all results have been this dramatic, each NeoPlas melanoma patient has had results significantly better than those with standard therapy. Eradication of tumors or long-term stability has occurred in most patients; others have seen a substantial slowing of progression.

The new protocol incorporates a unique combination of FDA-approved drugs used by millions of people for other applications. When administered alone, these drugs show some benefit against cancer, but not enough to make a difference for most patients. The combination of the medicines, however, allows lower, more tolerable dosages and provides effectiveness not seen in previous, single-drug studies.

The NeoPlas treatment disables certain abnormal cellular processes many of the aggressive malignancies share. Based on experience and relevant lab research to date, staff members expect the best results for: melanoma, pancreatic cancer, colon cancer, renal (kidney) cancer, mesothelioma, and a group of sarcomas, including osteosarcoma, chondrosarcoma and malignant fibrous histiocytoma. The regimen is not expected to have significant benefit against brain tumors.

The most notable side effect is fatigue. Most patients ne
'/>"/>

SOURCE NeoPlas Innovation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
2. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
3. Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
4. Patients Own Infection-Fighting T Cells Put Late-Stage Melanoma Into Long-Term Remission - Without Chemotherapy or Radiation
5. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
6. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
7. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
8. Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma
9. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
10. Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
11. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... MENLO PARK, Calif. , May 29, ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies in new orphan drug indications, presented additional ... Cancer Research (AACR) Advances in Brain Cancer Research ... product candidate VAL-083 (dianhydrogalactitol) to treat ...
(Date:5/29/2015)... OAKS, Calif. , May 29, 2015 /PRNewswire/ ... pooled data from two pivotal Phase 3, global, ... calcimimetic, for the treatment of secondary hyperparathyroidism (SHPT) ... hemodialysis. Both studies met the primary endpoint, demonstrating ... AMG 416 groups achieved a greater than 30 ...
(Date:5/28/2015)... , May 28, 2015  Eli Lilly and Company ... its previously announced cash tender offer for up to $1.6 ... securities. Holders of notes who tendered, and did ... New York City time, on May ... for purchase by Lilly, are eligible to receive the total ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... (Nasdaq: MYL ) today confirmed that the ... Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation in connection with ... with the U.S. Food and Drug Administration (FDA) for ... 0.05 mg/day, 0.075 mg/day and 0.1 mg/day. This product ...
... would tax the companies that manage prescription drug benefits ... owners they contract with – will drive up prescription ... Management Association (PCMA), the trade group for America,s pharmacy ... of America,s businesses, state and federal government agencies, and ...
Cached Medicine Technology:Mylan Confirms First-to-File Patent Challenge Relating to Vivelle-Dot® 2PCMA: Mississippi's 'Secret Prescription Drug Tax' Will Raise Costs 2
(Date:5/29/2015)... 29, 2015 Intermountain Healthcare ... with Stratus Video Interpreting for ... better communication and timely care for patients ... loss. Stratus’ video remote interpreting (VRI) services ... staff to quickly access qualified medical interpretation ...
(Date:5/29/2015)... 29, 2015 The print component of ... circulation of approximately 250,000 and an estimated readership of ... vast social media strategy, and across a network of ... digital version of the campaign, click here. ... publication. Inside, the actress, model and producer details her ...
(Date:5/29/2015)... 2015 Mediaplanet has joined forces with ... Skin Health is a cross-platform campaign with a ... of New York, Los Angeles, and Chicago, the campaign ... digital counterpart will reach a national audience through one ... the Skin Health campaign and Colorescience, click here ...
(Date:5/29/2015)... OncLive proudly announces the 2015 ... recognized by a panel of eminent oncologists for landmark ... Honorees will be introduced and celebrated TONIGHT at the ... 8:30-11:00 p.m. CDT at The Chicago Illuminating Company, 2110 ... recognized for groundbreaking accomplishments, in fields including translational research, ...
(Date:5/29/2015)... May 29, 2015 Healthpointe is ... with specialists, physical therapy, and injections , For ... back and/or lower back pain, Healthpointe has a ... for herniated discs, disc protrusions and other causes ... , Healthpointe’s team of renowned surgeons are now ...
Breaking Medicine News(10 mins):Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 4Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3
... University of Texas MD Anderson Cancer Center has been awarded ... caused by head and neck cancer radiation treatment, can be ... The $2.7 million grant awarded by the National Cancer ... a perfect score from peer scientists evaluating grant proposals for ...
... Doheny HealthDay Reporter , TUESDAY, March 22 ... for the recommended five years protects women from breast ... drug and it also shields some women from cardiovascular ... heart-disease risk reduction were noted 15 years after starting ...
... 22 (HealthDay News) -- Nurses often don,t speak up ... workers making mistakes that could harm patients, new research ... steps to reduce medical errors through measures such as ... automated medication-dispensing systems. But the study, which included ...
... Jenifer Goodwin HealthDay Reporter , TUESDAY, March 22 ... called fibrates is on the rise in the United States ... improve health, researchers say. Fibrates are often prescribed to ... high levels of triglycerides, a harmful form of fat circulating ...
... work in Lewy body dementia , the Harry T. ... gift, pledged over four years. Lewy body dementia, which combines ... , is the second most common form of dementia in ... and video resources, including excerpts from an interview with Drs. ...
... University has started recruiting patients for a new ... whether the cholesterol-reducing drug rosuvastatin is effective in ... laboratory research and population studies have shown that ... lowers cholesterol, had fewer colon polyps, which can ...
Cached Medicine News:Health News:UT MD Anderson receives grant for study of acupuncture in cancer 2Health News:Tamoxifen May Offer Long-Term Heart, Cancer Protection 2Health News:Tamoxifen May Offer Long-Term Heart, Cancer Protection 3Health News:Study: Reluctance to Speak Up Encourages Medical Errors 2Health News:Study Questions Rise in Use of Certain Cholesterol Drugs 2Health News:Study Questions Rise in Use of Certain Cholesterol Drugs 3Health News:Study Questions Rise in Use of Certain Cholesterol Drugs 4Health News:Gift will allow Mayo researchers to explore cause of dementia in the elderly 2Health News:Gift will allow Mayo researchers to explore cause of dementia in the elderly 3Health News:Jefferson clinical trial: Can a cholesterol drug prevent colon cancer? 2
... patented Miami J® collar is designed to ... patient. Break-through fabrics inhibit decubitus during long-term ... and speed recovery. And the unique ... any prefabricated extended wear collar. And kids ...
One-piece rigid cervical collar is designed to fit securely around the neck and mandible to provide immobilization and support of the cervical region...
Model C-10 is a four post cervical orthosis which controls flexion, extension, lateral flexion, rotation, and axial motion. Each post may be individually adjusted in height....
... Orthosis ensures comfort and immobilization ... anterior frame and occipital component. ... flow and easy application. Large ... For added comfort, removable, flannel-covered, ...
Medicine Products: